Several analysts have recently updated their ratings and price targets for GlaxoSmithKline plc (LON: GSK):

  • 9/20/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 1,900 ($24.80) price target on the stock.
  • 9/20/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Goldman Sachs Group Inc.. They now have a GBX 1,800 ($23.50) price target on the stock.
  • 9/16/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Beaufort Securities.
  • 9/16/2016 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 9/14/2016 – GlaxoSmithKline plc was downgraded by analysts at BNP Paribas to an “underperform” rating. They now have a GBX 1,520 ($19.84) price target on the stock.
  • 9/14/2016 – GlaxoSmithKline plc had its “sell” rating reaffirmed by analysts at Societe Generale. They now have a GBX 1,320 ($17.23) price target on the stock.
  • 9/13/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 1,900 ($24.80) price target on the stock.
  • 9/13/2016 – GlaxoSmithKline plc had its price target lowered by analysts at Jefferies Group from GBX 2,000 ($26.11) to GBX 1,900 ($24.80). They now have a “buy” rating on the stock.
  • 9/12/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at HSBC. They now have a GBX 1,970 ($25.71) price target on the stock.
  • 9/8/2016 – GlaxoSmithKline plc was downgraded by analysts at Societe Generale to a “sell” rating. They now have a GBX 1,320 ($17.23) price target on the stock, up previously from GBX 1,300 ($16.97).
  • 9/8/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Deutsche Bank AG.
  • 9/6/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Beaufort Securities.
  • 9/5/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 9/2/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 1,800 ($23.50) price target on the stock.
  • 8/23/2016 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a GBX 1,900 ($24.80) price target on the stock.
  • 8/17/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/12/2016 – GlaxoSmithKline plc had its price target raised by analysts at JPMorgan Chase & Co. from GBX 1,800 ($23.50) to GBX 1,900 ($24.80). They now have a “neutral” rating on the stock.
  • 8/10/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/9/2016 – GlaxoSmithKline plc was given a new GBX 1,885 ($24.61) price target on by analysts at Berenberg Bank. They now have a “neutral” rating on the stock.
  • 8/4/2016 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at BNP Paribas. They now have a GBX 1,560 ($20.36) price target on the stock.
  • 8/4/2016 – GlaxoSmithKline plc was given a new GBX 1,800 ($23.50) price target on by analysts at Independent Research GmbH. They now have a “neutral” rating on the stock.
  • 8/4/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a GBX 2,000 ($26.11) price target on the stock.
  • 8/2/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Beaufort Securities.
  • 7/29/2016 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at BNP Paribas.
  • 7/29/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a GBX 2,000 ($26.11) price target on the stock.
  • 7/28/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Bryan, Garnier & Co.
  • 7/28/2016 – GlaxoSmithKline plc was given a new GBX 1,755 ($22.91) price target on by analysts at Sanford C. Bernstein. They now have a “neutral” rating on the stock.
  • 7/28/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 1,700 ($22.19) price target on the stock.
  • 7/28/2016 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 7/27/2016 – GlaxoSmithKline plc was given a new GBX 1,650 ($21.54) price target on by analysts at S&P Global Inc.. They now have a “neutral” rating on the stock.
  • 7/27/2016 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 7/27/2016 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Citigroup Inc..

GlaxoSmithKline plc (LON:GSK) opened at 1640.50 on Wednesday. GlaxoSmithKline plc has a 52-week low of GBX 1,227.50 and a 52-week high of GBX 1,716.50. The company’s 50-day moving average price is GBX 1,655.81 and its 200 day moving average price is GBX 1,530.22. The stock’s market capitalization is GBX 79.74 billion.

The firm also recently announced a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be paid a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, August 11th. This represents a yield of 1.12%.

In other news, insider Cartwright,Stacey purchased 461 shares of the company’s stock in a transaction dated Friday, July 1st. The shares were purchased at an average cost of GBX 1,559 ($20.35) per share, for a total transaction of £7,186.99 ($9,381.27). Also, insider Witty,Sir Andrew P sold 10,000 shares of the firm’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.10), for a total value of £169,300 ($220,989.43).

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.